A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease

INTRODUCTION: Immune checkpoint inhibitors (ICIs) are increasingly used to treat cancers. Kidney immune-related adverse events (IRAEs) are now well recognized, with the incidence of IRAEs ranging from 2% to 5%. Most of the initial data related to kidney IRAEs have focused on acute interstitial nephr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitchlu, Abhijat, Jhaveri, Kenar D., Wadhwani, Shikha, Deshpande, Priya, Harel, Ziv, Kishibe, Teruko, Henriksen, Kammi, Wanchoo, Rimda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783581/
https://www.ncbi.nlm.nih.gov/pubmed/33426386
http://dx.doi.org/10.1016/j.ekir.2020.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783581/
https://www.ncbi.nlm.nih.gov/pubmed/33426386
http://dx.doi.org/10.1016/j.ekir.2020.10.002

Ejemplares similares